

**Biotechnology Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

June 30, 2021

	Shares	Value
<b>COMMON STOCKS<sup>†</sup> - 99.6%</b>		
<b>Biotechnology - 75.7%</b>		
Amgen, Inc.	40,084	\$ 9,770,475
Moderna, Inc.*	36,544	8,587,109
Gilead Sciences, Inc.	112,107	7,719,688
illumina, Inc.*	14,813	7,009,660
Regeneron Pharmaceuticals, Inc.*	11,656	6,510,342
Vertex Pharmaceuticals, Inc.*	30,420	6,133,585
Biogen, Inc.*	16,380	5,671,903
Alexion Pharmaceuticals, Inc.*	28,770	5,285,337
Corteva, Inc.	106,911	4,741,503
Seagen, Inc.*	28,229	4,456,794
CRISPR Therapeutics AG*	25,300	4,095,817
Horizon Therapeutics plc <sup>†</sup>	40,545	3,796,634
Exact Sciences Corp.*	30,184	3,752,173
Bio-Rad Laboratories, Inc. — Class A*	5,700	3,672,453
Alnylam Pharmaceuticals, Inc.*	21,438	3,634,170
Novavax, Inc.* <sup>1</sup>	16,780	3,562,562
Incyte Corp.*	42,214	3,551,464
BioMarin Pharmaceutical, Inc.*	38,509	3,213,191
BioNTech SE ADR <sup>†</sup>	13,510	3,024,619
Guardant Health, Inc.*	23,466	2,914,242
Beam Therapeutics, Inc.*	22,270	2,866,372
Zai Lab Ltd. ADR <sup>†</sup>	14,690	2,599,983
BeiGene Ltd. ADR <sup>†</sup>	7,410	2,543,038
Bridgebio Pharma, Inc.*	40,060	2,442,058
Fate Therapeutics, Inc.*	27,430	2,380,650
Arrowhead Pharmaceuticals, Inc.*	28,544	2,364,014
Mirati Therapeutics, Inc.*	14,533	2,347,515
United Therapeutics Corp.*	12,964	2,325,871
Twist Bioscience Corp.*	17,160	2,286,570
Acceleron Pharma, Inc.*	18,042	2,264,090
Halozyne Therapeutics, Inc.*	47,250	2,145,622
Biohaven Pharmaceutical Holding Company Ltd.*	21,560	2,093,045
Ultragenyx Pharmaceutical, Inc.*	21,759	2,074,721
Editas Medicine, Inc.*	35,580	2,015,251
Ionis Pharmaceuticals, Inc.*	50,319	2,007,225
TG Therapeutics, Inc.*	50,160	1,945,706
Blueprint Medicines Corp.*	21,690	1,907,852
Exelixis, Inc.*	97,663	1,779,420
Arena Pharmaceuticals, Inc.*	24,800	1,691,360
Iovance Biotherapeutics, Inc.*	64,674	1,682,817
ACADIA Pharmaceuticals, Inc.*	64,613	1,575,911
Sage Therapeutics, Inc.*	26,716	1,517,736
Emergent BioSolutions, Inc.*	23,906	1,505,839
PTC Therapeutics, Inc.*	32,748	1,384,258
VeracYTE, Inc.*	34,450	1,377,311
Amicus Therapeutics, Inc.*	132,550	1,277,782
Bluebird Bio, Inc.*	37,115	1,186,938
Global Blood Therapeutics, Inc.*	33,635	1,177,898
Inovio Pharmaceuticals, Inc.* <sup>1</sup>	126,450	1,172,191
ChemoCentryx, Inc.*	58,930	789,073
<b>Total Biotechnology</b>		<u>157,831,838</u>
<b>Pharmaceuticals - 14.5%</b>		
AbbVie, Inc.	101,742	11,460,219
Intellia Therapeutics, Inc.*	24,500	3,966,795
Viatis, Inc.	235,567	3,366,252
Jazz Pharmaceuticals plc <sup>†</sup>	16,559	2,941,541
PRA Health Sciences, Inc.*	16,154	2,668,802
Neurocrine Biosciences, Inc.*	25,446	2,476,405
Sarepta Therapeutics, Inc.*	25,899	2,013,388
Pacira BioSciences, Inc.*	22,151	1,344,123
<b>Total Pharmaceuticals</b>		<u>30,237,525</u>
<b>Healthcare-Products - 6.1%</b>		
Bio-Techne Corp.	7,725	3,478,258
Novocure Ltd.*	12,863	2,853,271
Natera, Inc.*	23,950	2,719,043
Adaptive Biotechnologies Corp.*	48,710	1,990,291
CareDx, Inc.*	19,480	1,782,810
<b>Total Healthcare-Products</b>		<u>12,823,673</u>
<b>Healthcare-Services - 3.3%</b>		
Syneos Health, Inc.*	28,604	2,559,772
Invitae Corp.* <sup>1</sup>	64,550	2,177,272
Medpace Holdings, Inc.*	11,621	2,052,617
<b>Total Healthcare-Services</b>		<u>6,789,661</u>
<b>Total Common Stocks</b>		<u>207,682,697</u>
(Cost \$108,128,482)		
<b>RIGHTS<sup>†††</sup> - 0.0%</b>		
<b>Biotechnology - 0.0%</b>		
Clinical Data, Inc.	24,000	—
<b>Total Rights</b>		<u>—</u>
(Cost \$—)		
	<b>Face Amount</b>	
<b>REPURCHASE AGREEMENTS<sup>††2</sup> - 0.6%</b>		
J.P. Morgan Securities LLC issued 06/30/21 at 0.05% due 07/01/21	\$ 745,038	745,038
Barclays Capital, Inc. issued 06/30/21 at 0.03% due 07/01/21	293,321	293,321
BofA Securities, Inc. issued 06/30/21 at 0.04% due 07/01/21	287,570	287,570
<b>Total Repurchase Agreements</b>		<u>1,325,929</u>
(Cost \$1,325,929)		
	<b>Shares</b>	
<b>SECURITIES LENDING COLLATERAL<sup>†3</sup> - 1.7%</b>		
<b>Money Market Fund</b>		
First American Government Obligations Fund — Class Z, 0.02% <sup>4</sup>	3,575,002	3,575,002
<b>Total Securities Lending Collateral</b>		<u>3,575,002</u>
(Cost \$3,575,002)		
<b>Total Investments - 101.9%</b>		
(Cost \$113,029,413)		<u>\$ 212,583,628</u>
<b>Other Assets &amp; Liabilities, net - (1.9)%</b>		<u>(4,002,505)</u>
<b>Total Net Assets - 100.0%</b>		<u>\$ 208,581,123</u>

**Biotechnology Fund****SCHEDULE OF INVESTMENTS (Unaudited)**

June 30, 2021

- \* Non-income producing security.  
† Value determined based on Level 1 inputs.  
†† Value determined based on Level 2 inputs.  
††† Value determined based on Level 3 inputs.  
1 All or a portion of this security is on loan at June 30, 2021.  
2 Repurchase Agreements.  
3 Securities lending collateral.  
4 Rate indicated is the 7-day yield as of June 30, 2021.

ADR — American Depositary Receipt  
plc — Public Limited Company